Sorafenib, Gemcitabine, and Capecitabine in Treating Patients With Unresectable and/or Metastatic Kidney Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00121251
Recruitment Status : Active, not recruiting
First Posted : July 21, 2005
Last Update Posted : September 13, 2017
Information provided by (Responsible Party):
National Cancer Institute (NCI)

No Study Results Posted on for this Study
  Recruitment Status : Active, not recruiting
  Estimated Primary Completion Date : September 30, 2017
  Study Completion Date : No date given